Interleukin 6, Interleukin 1 alpha, and Bone morphogenetic protein 2 (IL-6, IL-1A, and BMP-2)

This entry represents a composite of three distinct signaling proteins: Interleukin 6 (IL-6), Interleukin 1 alpha (IL-1α), and Bone morphogenetic protein 2 (BMP-2). Interleukin 6 is a pleiotropic cytokine that plays a central role in the acute phase response and the transition from innate to adaptive immunity, often targeted in autoimmune diseases like rheumatoid arthritis (UniProt P05231). Interleukin 1 alpha is a potent pro-inflammatory cytokine involved in the initiation of inflammatory cascades and is frequently associated with skin diseases and cancer-related cachexia (UniProt P01583). Bone morphogenetic protein 2 is a member of the TGF-beta superfamily that induces bone and cartilage formation, utilized clinically in orthopedic procedures to promote bone healing (UniProt P12643). While all three are significant therapeutic targets, they operate through distinct signaling pathways and receptors. Drugs targeting these molecules include monoclonal antibodies for the interleukins (e.g., tocilizumab, bermekimab) and recombinant proteins for BMP-2 (e.g., dibotermin alfa). The grouping of these three molecules is atypical for a single target profile as they represent diverse biological systems.

Other names

IL6IL1ABMP2B-cell stimulatory factor 2IFNB2Hematopoietin-1Bone morphogenetic protein 2A

Interleukin 6 and Interleukin 1 alpha are targeted by monoclonal antibodies that bind the ligand or its receptor to inhibit downstream inflammatory signaling pathways such as JAK/STAT or NF-κB (DrugBank DB06372). Bone morphogenetic protein 2 is administered as a recombinant protein to activate BMP receptors (Type I and II), triggering the SMAD signaling pathway to induce osteoblast differentiation and bone formation (DrugBank DB00057).